Corporate Presentation

April 2024





Developing therapeuticsat the forefront of oncology

Note on the presentation and forward-looking statements

This document does not constitute a public offering in the meaning of the Regulation (EU) 2017/1129 of the European Parliament and of the Council, or any other offer or invitation to acquire any Company's securities, nor the incentive to submit bids for the acquisition or subscription of the Company's securities.

This document does not constitute information about the Company's securities and the terms and conditions of their acquisition or offering sufficient grounds to decide whether to purchase or acquire such securities. In particular, the document does not constitute an offer of securities for sale in the United States, nor may the securities be offered or sold in the United States absent registration under the Securities Act or in reliance upon an available exemption from the registration requirements of the U.S. Securities Act and in compliance with applicable state securities laws.

The forward-looking statements contained in this document, such as those relating to the Company's income, results or development in particular in connection with the clinical development of company's projects, are based on a number of assumptions, expectations and projections, and are subject to uncertainty and may change as a result of external or internal factors and should not be treated as binding forecasts. Neither the Company nor the persons acting on its behalf, in particular the members of the Company's Management Board, the Company's advisers nor any other person, provide any assurance that future expectations will be fulfilled, and in particular do not guarantee the future results or events of such statements and that the future results of the Company will not differ materially from the forward-looking statements.

The information in this document is subject to change. Neither the Company nor any other person is obligated to update them.



Ryvu at a glance

FIRST-IN-CLASS CLINICAL PIPELINE

RVU120

- First-in-class, selective, oral CDK8/19 inhibitor
- Fully-owned by Ryvu
- Two Ph II studies ongoing in AML/HR-MDS (mono and combo)
- Two additional Ph II studies planned in LR-MDS and MF

MEN1703

- First-in-class dual PIM/FLT3 kinase inhibitor in Phase II; DLBCL study to initiate
- Potential across hematology
- Partnered with Menarini Group

SMALL MOLECULE DISCOVERY PLATFORM: NOVEL SYNTHETIC LETHALITY TARGETS & IO PARTNERSHIPS

Developing small molecule therapies which address high-value emerging targets and pathways in oncology

SYNTHETIC LETHALITY

- PRMT5
- WRN
- Novel SL targets

IMMUNO-ONCOLOGY

- BioNTech: STING standalone license and multitarget research collaboration
- Exelixis: STING ADC collaboration





FULLY INTEGRATED RESEARCH & DEVELOPMENT ORGANIZATION

- LISTING: WSE:RVU (mWIG40 index); cash runway to Q1 2026
- TEAM: >290 employees, including ~200 scientists (with ~90 PhDs)
- SITE: Fully-owned, state-of-the-art 108,000 sq ft facility



Team with a strong track record of clinical development and shareholder value creation





Pawel Przewiezlikowski, MSc, MBA Krzysztof Brzozka, PhD, MBA **CEO** and Founder CSO





Nodthera ardigen

Miika Ahdesmäki, PhD, MBA CIO AstraZeneca bio/Ac ALMAC

Jakub Janowski, MSc **General Counsel**





Hendrik Nogai, MD CMO NB CAPITAL



Bartlomiej Konicki, MSc **Financial Director**

Selvita KPMG





Kamil Sitarz, PhD, MBA CO0





Tomasz Rzymski, PhD, MBA **Director of Translational Medicine**









Justyna Zoltek, MSc Director of HR Luxoft steps III

PIOTR ROMANOWSKI, M.D. Ph.D., CHAIRMAN	McKinsey pwc & Company	
SCOTT Z. FIELDS, M.D.	NOTIX AMGEN VERTEX (1990)	
THOMAS TURALSKI	2) revidea perceptive Acertafharma	
PETER SMITH, Ph.D	CATLASVENTURE SH3 Raded	

RAFAL CHWAST, MSc	COMARCH Nowy Styl Group
AXEL GLASMACHER, M.D.	40 BANNA ST. CONT.
TADEUSZ WESOLOWSKI, Ph.D	NEUCA



Broad pipeline addressing emerging targets in oncology

PROGRAM	INDICATION	DISCOVERY	PRECLINICAL	PHASE I	PHASE II	PARTNER	EXPECTED MILESTONES
CLINICAL PROJECTS							
	R/R AML/HR-MDS (RIVER-52) (monotheraphy)					LEUKEMIA & LYMPHOMA SOCIETY	Complete Ph I data in 2Q24; Initial Ph II data in 4Q24
RVU120	R/R AML (RIVER-81) (combination therapy)						Initial Ph II data in 4Q24
(CDK8/19)	Other Hematology (LR-MDS, MF)						Initiation of Ph II in mid-2024
	Solid Tumors						Complete Ph I data & Translational Studies in 2024
MEN1703 (SEL24) (PIM/FLT3)	DLBCL					MENARINI	Initiation of Ph II in mid-2024
DISCOVERY AND PRECLINICAL	PROJECTS						
SYNTHETIC LETHALITY							
PRMT5	SOLID TUMORS						IND-enabling Studies in 2024
WRN	SOLID TUMORS						Development Candidate in 2024
NOVEL TARGETS	ONCOLOGY						
IMMUNO-ONCOLOGY							
STING & MULTI-TARGET IMMUNE MODULATION COLLABORATION	ONCOLOGY					BIONTECH	
STING ADC	ONCOLOGY					EXELIXIS °	




RVU120: First-in-Class CDK8/19 Inhibitor in Hematologic and Solid Tumor Malignancies





RVU120 is a fully-owned CDK8/19 inhibitor currently in Phase II




Current RVU120 development plan could lead to three accelerated approvals in 2026-2027



RVU120: opportunities across a broad range of cancers

Blood Cancers & Disorders

Solid Tumors



Translational evidence in multiple tumor types, additional potential in combinations

 Single agent and combination potential across several solid tumors

RVU120 development plan is focused on hematological malignancies Phase II studies ongoing

٠

.

.

٠

٠



RVU120 for potential treatment of Acute Myeloid Leukemia (AML)


Acute Myeloid Leukemia

- Most common, highly aggressive type of acute leukemia in adults
- Poor outcomes in most patients¹
- Annual US incidence ~20,500^{2;} 11,300 deaths in the US in 2023²



Preclinical Evidence: AML

CD34+ AML patient-derived xenografts:






DNMT3A and NPM1 are candidates for patient selection markers in AML

DNMT3A/NPM1 mutated AML is dependent on dysregulation of HOX genes

- Low nM activity on CDK8/19: RVU120 reduces the viability of AML PDCs, in particular those bearing recurrent DNMT3A and NPM1 mutations
- Open chromatin status of DNMT3A and NPM1 mutants makes cells more sensitive to transcriptional changes induced by RVU120
- DNMT3A and NPM1 mutants are dependent on high expression of MEIS1 and homeobox (HOX) genes that can be regulated by RVU120
- Currently no approved therapies targeting DNMT3A or NPM1 mutations in AML

Loss of viability with RVU120 treatment





DNMT3A and/or NPM1




Combination potential with venetoclax was shown in preclinical models

Synergistic activity was demonstrated in venetoclax sensitive and venetoclax resistant models:





Synergy is driven by regulation of MCL-1:



RVU120 OPPORTUNITY

Fast-to-market strategy as monotherapy in a potentially selected population and broad opportunity in early lines of treatment in combination



RVU120 validated preclinically as a drug candidate in myelofibrosis (MF)


Opportunity in myelofibrosis

- Growing market with many patients undiagnosed or not treated due to lack of treatment options
- Long durations of therapy and unmet medical need, for example in patients with severe anemia

RVU120 in myelofibrosis

- RVU120 alone and in combination can reduce symptoms and has disease-modifying potential in MF
- Favorable RVU120 toxicity profile may enable targeting of patients who are not eligible for ruxolitinib treatment
- Preclinical results confirm RVU120's potential in ruxolitinib r/r MF patients
- Synergy with ruxolitinib indicates potential for combination therapy in the frontline setting and in patients with suboptimal response to JAKi

Mechanism of RVU120 activity in MF



Reduction of bone marrow fibrosis









Clinical results demonstrating erythroid improvement support further studies in HR-MDS and LR-MDS

Growing number of patients treated with RVU120 show hematological improvement

Several patients with AML and HR-MDS showed signs of improved erythropoiesis in RIVER-51:

- Increasing hemoglobin and platelets counts
- Transfusion independence
- Molecular changes indicating on-target activity

Overall non-clinical and clinical findings provide a strong rationale for RVU120 as a novel drug candidate in MDS – both high- and low-risk

> \$ \$ \$

AML patient

- High-risk group
- Transfusion dependent
- 3 prior lines of treatment


RVU120 treatment (100mg)

• Disease Stabilization (SD)


ζØ

- Erythroid Response (HI-E)
- Platelet Response (HI-P)

Induction of erythroid gene expression programs confirmed by RNAseq



Induction of erythropoiesis confirmed by flow cytometry






RVU120: Phase I AML/MDS study – RIVER-51

STUDY POPULATION

- Patients with relapsed/refractory AML or high-risk MDS
- No upfront patient stratification

TREATMENT

Three-week cycle: Single oral dose of RVU120 every other day for a total of 7 doses/cycle followed by one week off





5 SITES IN POLAND





Data from the initial dose-escalation cohorts updated at ASH Conference in December 2023 Phase II enrollment to initiate in Q1 2024



RVU120 has a favorable safety profile at doses tested to date

Antiemetic prophylaxis introduced recently improves compliance and tolerability at higher doses

RVU120 was well tolerated at doses between 10 and 250 mg

- No DLTs and no study drug interruptions due to adverse drug reactions were observed
- No trend for increased toxicity at higher doses was observed during the dose escalation phase
- The most frequent TEAEs were nausea/vomiting, manageable with common antiemetics
- Among three patients treated at 250 mg and receiving recommended antiemetic prophylaxis, none experienced nausea or vomiting in the entire first cycle of treatment

Most common* Treatment	RVU120 (10-250 mg)			
Emergent Adverse Events (TEAE)	Any grade, n (%)	Grade 3-5, n (%)		
Nausea	24 (60%)	0		
Vomiting	16 (40%)	1 (2%)		
Thrombocytopenia	11 (28%)	8 (20%)		
Febrile neutropenia	9 (22%)	8 (20%)		
Decreased appetite	7 (18%)	1 (2%)		
Pneumonia	7 (18%)	7 (18%)		
Cough	6 (15%)	0		
Hypokalemia	6 (15%)	0		

* Most common TEAEs occurring in at least 15% of enrolled patients



RIVER-51 clinical update at ASH 2023: 14 of 28 (50%) evaluable patients showed clinical benefit


Data cut-off: Nov 10, 2023

A total of 38 patients have been treated (28 evaluable)

- Median age 72 years
- 34 patients had AML and 4 had HR-MDS
- Patients relapsed or were refractory to a median of 3 prior lines of therapy


Clinical benefits

- 9 clinically significant BM blast reduction (1 CR, 1 MLFS, 3 marrow CRs, and 4 other clinically relevant BM blast reductions)
 - 1 patient with double leukemic clones and BM blast reduction received a transplant after nearly 4 months of treatment
- 5 patients with erythroid hematological improvement (HI-E), 4 of those became transfusion-independent, of which 2 normalized also their Grade 3 thrombocytopenia
- The dose of 250 mg was well tolerated in all three patients, without gastrointestinal events and selected for Phase II development





Patients with NPM1- and DNMT3A-mutated AML and HR-MDS achieved significant blast reductions



After the disclosure of the chart at the ASH Annual Meeting & Exposition a further decrease of blasts from 24% to 3% (88% reduction) was reported in patient 111-001 consistent with an outcome of MLFS.





Clinical activity for RVU120 was observed in multiple populations

NPM1 and DNMT3A mutations

An NPM1 mutation was identified in 2 pts who received RVU120

- pt 103-002: achieved a **CR** with skin leukemia resolution, this patient had a co-occurring DNMT3A mutation
- pt 108-001: disease control at the beginning of C2, but progressed after missing 4 doses in cycle 2 due to SAE (cholecystitis) not related to study drug

Three additional patients had a DNMT3A mutation without NPM1 mutation

- pt 103-001: HR-MDS; maintained 0-4% Blasts in the BM up to C25 (≥ 18 months of treatment) in addition to erythroid hematological improvement
- pt 106-005: 37% BM blast reduction in C2
- pt 108-002: **marrow CR** in C2 and is ongoing in C7 with BM fibrosis reduction and RBC transfusion reduction


HR-MDS

- 4 pts with HR-MDS treated were failing
 1-5 prior lines of treatment, including hypomethylating agents, and were heavily transfused prior to study entry
- 3 of these pts had >10 % blasts at baseline, all of them met the Cheson criterion of marrow CR during treatment with RVU120




RVU120 achieved target engagement levels between 50-70% at a dose of 250mg

These levels are expected to result in robust antileukemic efficacy



RVU120 dose - pSTAT5 inhibition

RVU120 concentration – pSTAT5 inhibition



- Pharmacodynamic (PD) activity of RVU120 was assessed by measuring changes to baseline in the CDK8-specific phosphorylation site of STAT5 (S725) from patient-derived leukemic cells *ex vivo*
- pSTAT5 percentage change at steady state (CxD13) represents the target engagement of RVU120


 Results of RVU120-induced pSTAT5 changes from patients enrolled in CLI120-001 and from the concomitant phase 1 study in patients with solid tumors show a tight correlation between pSTAT5 inhibition and drug exposure at doses up to 375mg





RVU120: Phase I Solid Tumor study – AMNYS-51

2 SITES IN POLAND + 3 SITES IN SPAIN



Preliminary data from the initial dose-escalation cohorts were presented at ESMO in October 2023





AMNYS-51 - ESMO 2023 data release

39 patients treated at doses up to 400 mg

Data cut-off: Sept 26, 2023


- A total of 39 patients have been treated in 8 cohorts
- Patients were unselected and heavily pretreated
- RVU120 demonstrates a favorable safety profile. No dose limiting toxicities (DLTs) or other safety signals were observed, confirming CDK8/19 inhibition as a viable approach for cancer therapies.
- Low grade nausea and vomiting were the most frequent AEs, contributing to suboptimal tolerability in Cohort 7
- Out of 12 patients who achieved a stable disease on RVU120, treatment in 8 patients lasted longer than on previous therapy line
- Trend to longer treatment duration was observed in patients with adenoid cystic carcinoma
- Dose schedule optimization will continue

cohort (mg)	patient	disease	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 mor
	4801-003 ¹	Adenoid Cystic Carcinoma of Trachea	
1 (75)	4802-001	Gastric Cancer	
	4801-004	Thymic Carcinoma	
	4801-006	TNBC	
2 (100)	3401-008	Metastatic Breast Cancer	
	4801-005	Pancreatic Cancer	
	4802-013 ²	Colorectal Cancer	
2 (125)	4801-015 ³	Mucoepidermal Lung Cancer	
3 (125) -	4801-010	Non-Seminomatous Germ-Cell Tumor	
	3403-014	Breast Cancer	
	3403-023 ⁴	Nasopharyngeal Adenoid Cystic Carcinoma	
	4802-019	Rhabdomyosarcoma	
4 (135)	4802-016	Colorectal Cancer	
	3402-018	Pancreatic Cancer	Legend
5.	4801-017	TNBC	
	4801-024	Pancreatic Cancer	PD SD not evaluable
	4802-025	Mucoepidermoid Cancer	ongoing treatment
5 (175)	4801-0335	Uterine Body Cancer	1: Patient was dose escalated from 75mg to
	3402-020	Colorectal Cancer	100mg in Cycle 12 and to 125mg in Cycle 14
	3401-021	Pancreatic Cancer	and to 135mg in Cycle 17
	4801-028 ⁶	Parotid Gland Adenoid Cystic Cancer	 Patient was dose escalated from 125mg to 135mg in Cycle 7
-	4801-0397	Colorectal Cancer	³ : Patient was dose escalated from 125mg to
-	3402-026	Colorectal Cancer	135mg in Cycle 5
-	3403-044	Cervix Cancer	A: Patient was dose escalated from 135mg to
6 (250)	3402-037	TNBC	175mg in Cycle 7 and to 250mg in Cycle 15
	4802-027	Colorectal Cancer	5: Patient was dose escalated from 175mg to 250mg in Cycle 2
-	3403-047	Adenoid Cystic Cancer	Patient was dose reduced from 250mg to
977 1977	3401-052	Adrenocortical Cancer	175mg in Cycle 3
-	3401-046	Cecal Cancer	7: Patient was dose reduced from 250mg to
	4802-049	Colorectal Cancer	175mg in Cycle 2 Patient treated at 400mg
8 (300) -	3401-051	Pancreatic Cancer	Reasons for study discontinuation:
	3402-034	Colorectal Cancer	disease progression
-	4801-042	Gastric cancer	Other reason
-	3401-043	Colorectal Cancer	+ + death
7 (375/	3402-032	Colorectal Cancer	
400)	3403-036	Esthesioneuroblastoma	
-	3402-040	Colorectal Cancer	
-	3401-045 ⁸	Prostate Cancer	
1.5	4801-030	Sarcoma	



Data generated in **RIVER-51** study support further development of RVU120, primarily in AML, HR-MDS, LR-MDS and MF

RIVER-51 (Phase I)








RIVER-52 : Phase II study with RVU120 as a single agent

Based on convincing translational rationale and clinical data, patients will be selected based on the disease features and genetic background

STUDY DESIGN

- Primary endpoints:
 - Rate of CR, CRh, CRi, with and without MRD, and DoR
- Secondary endpoints:
 - Transfusion independence, Progression-free survival, Relapse-free survival (RFS), Overall survival
- For Part 2: including PRO and HRQoL change from baseline
- Population: AML or HR-MDS with >10% blasts in BM and no alternative treatment
- Estimated enrolment: 134 patients in total




Ongoing assessment of Part 1 will drive selection of population for Part 2





RIVER-81 : Phase II study testing RVU120 in combination with venetoclax



STUDY DESIGN

- Primary endpoints:
 - Rate of CR, CRh, CRi, with and without MRD, and DoR
- Secondary endpoints: Transfusion independence, PFS, RFS, OS
- For Part 2: including PRO and HRQoL change from baseline
- Population: r/r Ven-failed AML, no alternative treatments
- Approx. **57-98 patients** planned
- Up to 50 clinical sites planned globally



 RIVER-81 is supported in part by a €13.3M grant from the Polish Medical Research Agency (ABM)



Dose finding in patients with relapsed/refractory AML after failing a venetoclaxbased regimen

24

Clinical Benefit CR/CRh/CRi, with and without MRD, and DoR

PART 2

Expansion Cohort at selected dose of RVU120 and venetoclax Simon 2-stage design



REMARK : RVU120 in LR-MDS – IIT conducted by Prof. Uwe Platzbecker and the EMSCO network

STUDY DESIGN

- Population:
 - Relapsed/refractory low-risk MDS for the treatment of anemia in patients failing available options
 - Opportunity for the first line (1L) setting
- Primary endpoint:
 - Erythroid response (HI-E) according to IWG 2018 criteria
- Secondary endpoint:
 - RBC transfusion independence
 - Hb improvement
 - Quality of life (QoL)
 - Disease progression according to IWG 2018 criteria
 - Mutational pattern and burden of selected genes and their influence on response



PHASE II

Patients failing available options

Enrollment of approx. 40 patients planned

ONGOING ASSESSMENT OF PHASE II WILL DRIVE FURTHER DEVELOPMENT

IIT

- Study will be conducted as an Investigator Initiated Trial with Prof. Uwe Platzbecker within EMSCO (European Myelodysplastic Neoplasms Cooperative Group)
- Enrollment planned in approx. 25 sites in EU




Prof. Uwe Platzbecker

- Co-founder and chairman of EMSCO and co-chairman of the European Hematology Association Scientific Working Group on MDS
- Primary focus on myelodysplastic syndromes (MDS) and its treatment
- Worked on trials assessing luspatercept (Reblozyl) and imetelstat in patients with LR-MDS




Clinical development of RVU120 focuses on hematologic malignancies, while translational research explores additional opportunities



Translational research is ongoing to support current clinical trials and to explore additional indications, including: medulloblastoma, sarcoma, TNBC, and other (undisclosed) indications



Phase II clinical development of RVU120 with a global footprint





RVU120 market potential in hematological malignancies

AML (Acute Myeloid Leukemia)

- The most common, highly aggressive type of acute leukemia occurring in adults; unfavorable outcomes for most patients⁽¹⁾
- Annual incidence in the US at ~20,500 with an estimated 11,300 deaths in the US in 2023⁽²⁾
- Venclexta (venetoclax) sales estimated to exceed USD 3.5 bn in 2025⁽³⁾

MDS (Myelodysplastic Syndrome)


- Disease leading to bone marrow damage, classified as cancer
- Growing market due to faster diagnosis of the disease and potential new therapies
- US incident cases expected to increase from 36,000 in 2018 to 46,000 in 2028⁽⁴⁾
- Reblozyl (luspatercept) projected peak sales of USD 2 bn

MF (Myelofibrosis)

- MF is a bone marrow disease characterized by JAK mutations; often leads to severe anemia
- Chronic disease with long duration of therapy; US prevalence is estimated to be ~13,000 patients⁽⁴⁾
- CTI BioPharma was acquired for USD 1.7 bn in May 2023 – the lead asset is Vonjo (pacritinib) - a JAK inhibitor with accelerated approval in a subset of MF











MEN1703 (SEL24): First-in-Class PIM/FLT3 Inhibitor





MEN1703 (SEL24)

Licensed to Menarini Group, currently in Phase II

PARTNERSHIP AGREEMENT WITH MENARINI GROUP (2017)

PROVEN SAFETY AND CLINICAL ACTIVITY

- EUR 4.8m upfront payment
- EUR 3.5m further milestone and translational research funding at Ryvu in 2017-2021
- Possible additional EUR 80m bio-dollar value + royalties
- Menarini conducts and funds all research and development costs

- Phase II clinical data (EHA2022) indicate efficacy in AML with IDH1/IDH2 gene mutations, similar to other drugs used as monotherapy
- Manageable safety profile
- Orphan drug designation (ODD) granted by FDA

Future directions – 2023+

DLBCL

Development to continue with the initiation of a **new Phase II** study in relapsed/refractory diffuse large B-cell lymphoma (DLBCL)

Future Opportunities

- Ongoing translational work supports potential development in other hematologic indications
- Development in AML to be deprioritized

Partnership

- As of September 2023, Ryvu has become Menarini's operational partner for Phase II execution
- The licensing partnership with Menarini remains unchanged, with Menarini funding all R&D. The total milestones and royalties due to Ryvu upon achievement of certain events remains unchanged

Unmet medical need and high commercial potential for MEN1703 in DLBCL

DLBCL (DIFFUSE LARGE B-CELL LYMPHOMA)

- Non-Hodgkin's lymphomas (NHL) are a heterogeneous group of lymphoproliferative disorders with DLBCL the being the most common type
- 30% to 40% of DLBCL patients will relapse during the first 2 years
- These patients often have significant comorbid conditions, which complicate the choices of often toxic treatment options and lead to decreased treatment rates in 3L+






COMMERCIAL POTENTIAL AND UNMET NEED

- Strong unmet medical need: estimated 23k incident DLBCL cases in North America in 2027 and 37k in the EU
- Targeted therapies have emerged as the dominant treatment options; choice of therapy is informed by type and response to prior therapies; timing of relapse; patient age, fitness, and comorbidities; disease kinetics; and product availability

RELAPSED/REFRACTORY PATIENTS INELIGIBLE FOR TRANSPLANT:

- Currently there is no optimal SOC defined for patients not candidates for transplant. Tafasitamab + lenalidomide reflect a preferred option for these patients. CAR-T cells and bispecific antibodies will move to the second line space
- The post CAR-T cell setting will require novel effective options in hard-totreat patients that are often not eligible for clinical trial enrolment due to prolonged cytopenias





Initiating Phase II in DLBCL

MEN1703 PROFILE

- First-in-class dual PIM/FLT3 inhibitor with a unique mechanism of action
- Differentiated activity in cellular models compared to selective PIM inhibitors (broader activity profile)

CLINICAL STUDIES TO DATE

- H1 2017- H1 2021 Phase I dose escalation and cohort expansion in R/R AML MTD of 125 mg established
- H2 2021 H1 2023 Phase II in IDH+ R/R AML
- 73 patients dosed so far across all studies, including 48 at R2PD
- Manageable safety profile
 - No QTc prolongation, no differentiation syndrome, no gastrointestinal tox
 - No hematologic toxicity

PHASE II in DLBCL

- Phase II study to consist of two parts: Part 1 pilot cohorts to establish combination dose and monotherapy efficacy followed by Part 2 cohort expansion
- Study locations: USA, Europe
- Phase II study to be initiated in mid-2024

ဂွီ



Small Molecule Platform with Focus on Synthetic Lethality





Integrated Discovery Engine at Ryvu



TARGET IDENTIFICATION AND VALIDATION

- Discovery of novel synthetic lethal target pairs and actionable oncogenic drivers
- Combination of the experimental engine and bioinformatic analysis using proprietary approaches



DRUG DISCOVERY

- Integrated, multidisciplinary processes: rapid lead identification/optimization with deep translational biology support
- Platform has delivered two projects in clinical development; multiple projects in discovery/research
- Team of ~200 scientists (with ~100 PhDs) with international expertise in drug discovery and track record in delivering new clinical candidates



RESEARCH PIPELINE

 Broad portfolio of synthetic lethal and immuno-oncology targets at various stages of the cycle – clinical candidate selection to target validation and hit finding

Synthetic Lethality

PRMT5, WRN, Novel SL targets

Immuno-Oncology

Partnerships with BioNTech (STING and multi-target IO collaboration) and Exelixis (STING ADCs)



Ryvu discovers novel synthetic lethal targets through multipronged target discovery, including the proprietary ONCO Prime platform

Isogenic cell line pairs

- "Classical" approach, genome-wide screens in isogenic pairs
- Focus on unexplored genomic alterations

Isogenic primary cells


Novel Target Discovery at Ryvu

ONCO Prime

 Gradual transformation of healthy primary cells with mutations typical for tumor evolution of specific tissue type

Patient-derived cells (PDCs)

- Clones derived from actual primary tumor tissue with tumor heterogeneity retained
- Collaboration with Polish academic institutions



ONCO Prime is the recipient of a PLN 26 million
 (~USD 6.6M) grant from the Polish Agency for
 Enterprise Development (PARP)


Novel Therapeutics

Ryvu pipeline:

- **PRMT** lead optimization
- WRN lead optimization
- Novel synthetic lethal targets
 - 10+ novel programs in various stages of discovery/research from target validation to hit finding
 - First novel targets emerging in ONCO Prime initiative with CRC primary patient-derived cells



ONCO Prime: Broad potential to identify novel cancer targets – first data in KRAS-driven CRC



36

RY VU

PRMT5 MTA-cooperative inhibitors


PRMT5 SL INHIBITOR PROGRAM IN RYVU

KEY RATIONALE	PRMT5 MTA-cooperative inhibitors exert synthetic lethal phenotype in MTAP deleted cells
MECHANISM OF ACTION	MTA-cooperative inhibitors
NOVELTY	Best-in-class potential (vs Mirati, Tango, Amgen)
TOP TUMOR INDICATIONS	MTAP deletions, up to 15% of all cancers, one of the largest genetically-defined population: pancreatic, lung, DLBCL, bladder, esophageal (by %: mesothelioma, GBM)
BIOMARKERS	MTAP deletion status SAM (plasma), SDMA (tissue) levels
STATUS	Lead optimization to candidate nomination is ongoing
TIMELINES	2024: IND-enabling studies initiation

37

RYVU HAS SL PRMT5 INHIBITORS WITH THE BEST-IN-CLASS POTENTIAL

Ryvu PRMT5 inhibitors demonstrate high cellular potency and MTA-cooperativity *in vitro* coupled with excellent in vivo activity



Multiparameter optimization of Ryvu PRMT5 inhibitors has resulted in:

- **Antiproliferative activity** for MTAP-deleted cells *in vitro:* high proportion of efficacy in large cell line panel
- Improved PK profile of Ryvu PRMT5 inhibitors demonstrated in different species PK studies
- Antitumor efficacy and target engagement achieve in vivo in responder DoHH-2 CDX model



Small molecule inhibitors of WRN

WRN INHIBITOR PROGRAM AT RYVU

KEY RATIONALE	Synthetic lethality of WRN with microsatellite instability (MSI-high)
MECHANISM OF ACTION	WRN inhibitors of ATPase activity selectively targeting tumors with microsatellite instability (MSI)
NOVELTY	First- or best-in-class potential Focus on selectivity (RecQ family)
TOP TUMOR INDICATIONS	Tumor agnostic with MSI-high vulnerability (~10-30% of colorectal, endometrial, gastric, ovarian cancers)
STATUS	Hit-to-lead generation ongoing
TIMELINES	2024/5: Lead to Development Candidate

Ryvu WRN inhibitors of ATPase activity selectively targeting tumors with microsatellite instability

Helicase function validated *in vitro* as critical requirement for synthetic lethal phenotype

1

2

3

Full in-house cascade developed


Ryvu identified small molecule inhibitors of WRN with strong and selective activity on MSI-H cells

In vivo efficacy study of the Ryvu WRN inhibitor exhibited **pronounced tumor growth inhibition (TGI)** in a microsatellite instability-high (MSI-H) colorectal cancer (CRC) xenograft model

X-ray of WRN helicase with Ryvu ligand



In vivo efficacy study



Administration day



BioNTech and Ryvu: global collaboration to develop and commercialize immune modulation small molecule candidates

Largest-ever Ryvu deal: November 2022





Multi-target discovery collaboration on small molecule programs in immune modulation

STING agonist license as a monotherapy and in combinations





- Multi-target research collaboration: Ryvu will conduct discovery and research activities to develop multiple small molecule programs targeting immune modulation in cancer and potentially other disease areas based on targets selected by BioNTech; BioNTech will hold exclusive worldwide development and commercialization rights.
- **STING agonist**: BioNTech receives a global, exclusive license to develop and commercialize Ryvu's STING agonist portfolio as standalone small molecules, including as monotherapy and in therapeutic combinations.

- Ryvu received €40 million from BioNTech, comprised of €20 million in upfront cash and a €20 million equity investment
- All R&D funded by BioNTech
- Ryvu is eligible for R&D and commercial milestones, and low single-digit royalties on product sales



Exelixis and Ryvu: exclusive license agreement to develop novel STING agonist-based targeted cancer therapies







Building STING-based antibody drug conjugates (ADCs)



Leveraging Ryvu's STING agonist portfolio and Exelixis's ADC technology





- Exclusive license agreement to combine Ryvu's small molecule STING agonists and STING biology know-how with Exelixis' antibody engineering, antibody-drug conjugate (ADC) technologies and drug development expertise
- Ryvu retains global rights for the development and commercialization of standalone STING agonists (licensed to BioNTech)

- 3M upfront cash; first milestone of \$1M achieved in Q1 2023; second milestone of \$2M achieved in Q1 2024
- Additionally, Ryvu is eligible to receive research funding, \$2M in near-term research-based milestones, and a double-digit milestone at first development candidate selection
- In total, Ryvu is eligible to receive milestones of over \$400 million plus tiered single-to-low double-digit royalties on annual net sales per product developed/commercialized



Corporate Progress





Full-Year Financial Results: 2023

\$ million	2022*	2023*
Revenues, incl.:	15.8	16.3
Partnering	8.7	11.2
Grants	6.6	4.9
Total Costs**, incl.:	26.4	37.6
Clinical Pipeline	6.4	13.0
Early Pipeline	12.8	15.8
G&A	7.2	8.8
EBIT**	-10.6	-21.3
EBITDA**	-7.7	-18.7
Net Results***	-13.8	-20.0

Cash position March 13, 2024 Ryvu Employees

\$66.5M

>270

Available EIB Venture Debt

€22M

Employees with PhD

~90

Partnering revenues in 2023: Exelixis (\$1.2 million), BioNTech (\$9.9 million recognized)

* recalculated from PLN using 4.4679 PLN/USD and 4.1823 PLN/USD – for 2022 and 2023, respectively

** excluding the impact of the non-dilutive, cash-neutral Employee Incentive Scheme (of \$5.0m, \$2.0m in 2022, and 2023 respectively) and valuation of NodThera (+\$2.0m (increase of costs), +\$0.9m in 2022, and 2023, respectively)

*** excluding the impact of the non-dilutive, cash-neutral Employee Incentive Scheme (of \$5.0m, \$2.0m, in 2022 and 2023 respectively)





EUR 22m venture debt obtained from the European Investment Bank

European Investment Bank

LONG-TERM FINANCING FOR INNOVATIVE GROWTH COMPANIES

Instrument structure adapted to the business model

Long-term financing repaid through *bullet repayment*, and remuneration independent of interest rates, partially secured by the Company's capital

2 Non-dilutive funding

Additional financial leverage to motivate the management board and existing shareholders, as well as significantly increasing the potential ROI for equity investors

Backing from one of the largest funding institutions in the EU

EIB financing is seen as an instrument that strongly validates the business model and attracts additional capital investors






Ryvu's Vision: from 2026, Ryvu will improve the lives of cancer patients worldwide

2024 KEY GOALS AND FINANCING

- RVU120 broad development (including potential fast-to-market strategy in AML/HR-MDS)
- SEL24 (MEN1703) to start Phase II in DLBCL (with Menarini Group)
- Advancement of one preclinical program into Phase I clinical trials
- Strengthening of Synthetic Lethality Platform and acceleration in the early pipeline progress
- Achieving financial milestones in existing collaborations (i.e. BioNTech, Exelixis, Menarini)
- At least one new partnering deal per year



2024 – DEVELOPMENT PLAN KEY ASSUMPTIONS

- Accelerating the pipeline to deliver cancer therapeutics to patients
- Capital for development secured; potential additional non-dilutive sources
- Significant increase of the company's value
- Development strategy includes alternative, de-risking partnering scenarios

2024 - KEY ANTICIPATED EVENTS

- Clinical data updates from RVU120 in Q2 and Q4
- New preclinical candidate in the early pipeline





PIPELINE

BUSINESS



Ryvu equity summary

IPO on WSE Corporate Split: Selvita and Ryvu	Nov 2014 Oct 2019
Ticker: WSE	RVU
52-Week Range ¹	PLN 53.50 – 72.40
Average Daily Volume (YTD) ¹	11,303
Market cap ¹	PLN 1,343 M (\$340m)
Shares outstanding	23.1 M
Cash ²	\$66.5m

	Top Holders ³	
1	Paweł Przewięźlikowski	18%
2	Allianz OFE	9.2%
3	BioNTech SE	8.3%
4	Nationale-Nederlanden OFE	7.9%
5	Tadeusz Wesolowski (incl. Augebit)	4.9%
6	PZU OFE	4.5%
7	Boguslaw Sieczkowski	4.0%
8	Allianz TFI	2.4%
9	Goldman Sachs TFI	2.1%
10	Norges Bank	2.1%
11	UNIQA OFE	1.8%
12	Generali OFE	1.5%

Analyst Coverage





Thank you

CONTACT DATA:

Ryvu Therapeutics S.A.

www.ryvu.com

ryvu@ryvu.com

ir@ryvu.com

